Trial Profile
A Randomized, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of Decitabine as Epigenetic Priming With Induction Chemotherapy in Pediatric Acute Myelogenous Leukemia (AML) Subjects
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 30 Jun 2022
Price :
$35
*
At a glance
- Drugs Decitabine (Primary) ; Cytarabine; Daunorubicin; Etoposide
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 24 Jun 2022 Status changed from completed to discontinued.
- 11 Dec 2018 A population pharmacokinetic model was developed by pooling decitabine concentration-time data from 5 adult (AML and MDS) and 2 pediatric (AML) studies (DACO-018, DACO-017, DACO-020, DACO-016, E7373-A001-101, E7373-G000-202 and DACOGENAML2004 trial); results published in the Journal of Clinical Pharmacology
- 06 Mar 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.